Physician profile
Ryan Brothers
NPI 1528597044
$15,804.27
in general payments reported to CMS, 2019-2025
31 companies · $7,421 in 2025
The $7,421 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $298 · 2021: $1,239 · 2022: $2,039 · 2023: $1,874 · 2024: $2,578 · 2025: $7,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,004 · Consulting Fee: $5,100 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $562 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,004.11 |
| Consulting Fee | $5,100.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $562.45 |
| Education | $205.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,254.56 | 2021-2025 | |
| Abbvie INC. | $1,988.53 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,342.59 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,151.31 | 2021-2025 | Ilumya |
| Janssen Biotech, INC. | $1,024.48 | 2020-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $644.70 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $417.02 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Novartis Pharmaceuticals Corporation | $407.26 | 2021-2025 | |
| Amgen INC. | $319.42 | 2021-2025 | Otezla, Enbrel, Otezla |
| Galderma Laboratories, L.P. | $301.19 | 2021-2025 | Nemluvio, Dysport, Aklief |
| Lilly USA, LLC | $289.99 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $260.51 | 2022-2025 | Sotyktu |
| Almirall LLC | $234.60 | 2022-2024 | Seysara, Klisyri |
| Incyte Corporation | $160.18 | 2022-2025 | Opzelura |
| Biofrontera INC. | $158.47 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $142.98 | 2022-2024 | Bimzelx |
| Verrica Pharmaceuticals INC. | $76.06 | 2023-2025 | Ycanth |
| Organon LLC | $60.81 | 2024-2025 | |
| Epi Health, LLC | $59.85 | 2019-2022 | |
| Dermavant Sciences, INC. | $58.24 | 2023 | Vtama |
| Journey Medical Corporation | $57.92 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.12 | 2022-2024 | Spevigo |
| Kerecis Limited | $52.21 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.58 | 2021-2022 | |
| Mimedx Group, INC. | $39.88 | 2024 | |
| Organogenesis INC. | $39.01 | 2024 | |
| Arcutis Biotherapeutics, INC. | $33.36 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $21.53 | 2021 | |
| Dermira, INC. | $21.00 | 2021 | |
| Mayne Pharma Commercial LLC | $20.58 | 2021 | |
| Genentech USA, INC. | $16.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Brothers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.